Table 1 Psychoactives and their corresponding mental health indications with the highest ranks from the Top10 predictions.
Psychoactive | Known effects and potential for abuse | Mental Health Indication |
|---|---|---|
3,4-dimethylmethcathinone | Stimulant with a high potential for abuse. | Anxiety Disorders |
3,4-dimethylmethcathinone | Stimulant with a high potential for abuse. | Depressive Disorder, Major |
1-naphthyl(1-pentyl-1h-indol-3-yl)methanone | Serious source of addiction | Alzheimer Disease |
dextromethorphan | Over the counter antitussive | Attention Deficit Disorder with Hyperactivity |
dexfenfluramine | Weight loss drug pulled for causing cardiac issues | Autistic Disorder |
3-fluoroamphetamine | Â | Bipolar Disorder |
2-fluoroamphetamine | Â | Cataplexy |
metamfepramone | Â | Delirium |
bupropion | Approved by the US FDA to treat depression | Depressive Disorder |
metamfepramone | Â | Tourette Syndrome |
ergoline | Used to treat migraine headaches | Erectile Dysfunction |
α-pyrrolidinopentiophenone | Stimulant | Learning Disorders |
2-fluoroamphetamine | Â | Narcolepsy |
isopropylamphetamine | Â | Obessive-compulsive disorder |
3-fluoroamphetamine | Â | Personality Disorders |
pyrovalerone | US Schedule V drug used for treatment of chronic fatigue | Phobic Disorders |
dextromethorphan | Over the counter antitussive | Psychotic Disorders |
3,4-dimethylmethcathinone | Â | Restless Legs Syndrome |
pyrovalerone | US Schedule V drug used for treatment of chronic fatigue | Schizophrenia |
pyrovalerone | US Schedule V drug used for treatment of chronic fatigue | Stress Disorders, Post-Traumatic |
α-pyrrolidinopentiophenone | Stimulant | Substance Withdrawal Syndrome |
pyrovalerone | US Schedule V drug used for treatment of chronic fatigue | Tobacco Use Disorder |
isopropylamphetamine | Â | Panic Disorder |
3,4-dimethylmethcathinone | Stimulant with a high potential for abuse. | Cocaine-Related Disorder |
3-fluoroamphetamine | Â | Binge-Eating Disorder |
